Exacerbation of Cardiovascular Complications in case of Covid-19 Patients and their Treatments

Abstract

The 2019 Corona virus Outbreak (COVID-19) is a scientific, medical and social challenge. The complexity of Severe Acute Respiratory Syndrome Corona virus 2 (SARSCoV2) focuses on the clinical course of unpredictable illnesses that can develop rapidly and cause serious complications leading to death. Systemic inflammation and lung problems can ensue, causing considerable morbidity and mortality. Acute coronary syndrome (ACS), arrhythmias, myocarditis, acute myocardial damage, heart failure, and other problems affect the cardiovascular system. Existing data about cardiovascular complications had been collected from the case study performed in China, Wuhan, and New York COVID-19 patients. In the case report of China, 16.7% out of 138 patients showed arrhythmias where heart failure was identified as a problem in 23% of patients in a retrospective study from Wuhan and 52% of non-survivors in China. On the other hand case studies on 18 COVID-19 patients with ST-elevation myocardial infarction (STEMI) on electrocardiogram (ECG) from New York were investigated; 6 patients (33%) reported chest pain, 14 patients (78%) reported ST-segment elevation, 6 patients (35%) reported regional wall motion abnormality on TTE, and 8 patients (44%) reported a clinical diagnosis of myocardial infarction and a total of 9 patients individuals (50%) had coronary angiography, with 6 patients (67%) of them showing obstructive disease. The cardiovascular consequences of COVID-19 infection are examined in this brief paper. The virus attaches to ACE2 (Angiotensin converting enzyme 2), allowing it to enter. COVID-19 therapy is currently being studied in conjunction with cardiovascular drugs. Therefore, emergency phy